An Exploratory Single Center Study of High-dose Treatment of Glivec in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Using Molecular Endpoints - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) Study.

Trial Profile

An Exploratory Single Center Study of High-dose Treatment of Glivec in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Using Molecular Endpoints - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) Study.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Imatinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 10 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov
    • 13 Oct 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top